Table 2.
Summative table of the discussed CD-based drug delivery systems correlated with the targeted types of cancer.
| CD-Based Nanocarrier(s) | Anti-Cancer Agent(s) | Type(s) of Cancer | Reference |
|---|---|---|---|
| Disulfide bond-linked permethyl-β-CD | Camptothecin | Lung cancer | [67] |
| α-CD, β-CD and (2-Hydroxypropyl)-β-CD | Porcupine inhibitor LGK974 | Lung cancer | [68] |
| β-CD coated with PLGA | Erlotinib | Lung cancer | [69] |
| Sulfobutylether-β-CD | Resveratrol | Lung cancer | [70] |
| Sulfobutylether-β-CD | Celastrol | Lung cancer | [71] |
| β-CD polycaprolactone block copolymers conjugated with folic acid | Metformin | Lung cancer | [72] |
| γ-CD, α-CD, and β-CD | New Zealand propolis | Colorectal adenocarcinoma, colon cancer, gastric cancer, esophageal squamous cell cancer | [75] |
| Hydroxypropyl-β-CD | Clausenidin | Colon cancer | [77] |
| β-CD/phillipsite | Oxaliplatin | Colorectal cancer | [76] |
| Folate-appended methyl-β-CD | Adamantane-grafted hyaluronic acid | Colorectal cancer | [78] |
| Cationic CD polymers | 5-fluorouracil and Interleukin-2 | Colorectal cancer | [79] |
| Folate-targeted polyethylene glycol-modified amphiphilic CD | Ginsenoside Rg3 and quercetin | Colorectal cancer | [80] |
| Folate-targeted polyethylene glycol-modified amphiphilic cationic CD | Docetaxel and siRNA | Colorectal cancer | [81] |
| Amphiphilic CDs coated with polyethyleneimine or chitosan | Camptothecin | Colorectal cancer | [82] |
| Poly(β-CD) | Platinum (IV) prodrug [Pt(IV)-ADA2] | Colorectal cancer | [83] |
| Folic acid–polyethylene glycol–β- CD | Doxorubicin | Liver cancer | [85] |
| β-CD modified with lactobionic acid coupled with polyethylene glycol | Doxorubicin | Liver cancer | [86] |
| β-CD-gated mesoporous silica nanoparticles functionalized with an azobenzene/galactose-grafted polymer | Doxorubicin | Liver cancer | [123] |
| Folic acid–polyethylene glycol–β- CD | Doxorubicin | Breast cancer | [91] |
| β-CD polymer | RNA-cleaving DNAzyme targeting c-Myc gene | Breast cancer | [92] |
| β-CD functionalized dendrimeric graphene oxide-magnetic nanoparticles | Doxorubicin | Breast cancer | [93] |
| D -α-Tocopherol polyethylene glycol 1000 succinate-modified β-CD | Genistein | Breast cancer | [94] |
| Folic acid–polyethylene glycol–β- CD | Adamantane and near-infrared fluorophore conjugate | Breast cancer | [95] |
| Permethyl-β-CD | Meso-tetraphenylporphyrin and meso-tetra(m-hydroxyphenyl)porphyrin | Breast cancer | [96] |
| β-CD and poly(2-ethyl-2-oxazoline) embedded with iron oxide nanoparticles | Doxorubicin hydrochloride | Breast cancer | [97] |
| β-CD-chitosan composite | L-asparaginase | Prostate cancer | [101] |
| β-CD | Carvacrol | Prostate cancer | [102] |
| β-CD loaded into polylactide stereocomplexed micelles | Doxorubicin | Cervical cancer | [103] |
| CDs loaded into pegylated liposomes | Pin1 inhibitor | Ovarian cancer | [105] |
| β-CD | Ticlopidine hydrochloride | Kidney cancer | [108] |
| Hydroxypropyl-β-CD | Taccalonolide A | Kidney cancer | [109] |
| CD-based polymers | Camptothecin | Brain cancer | [115] |
| CDs loaded into liposomes | Butylidenephthalide | Brain cancer | [116] |
| Hydroxypropyl-β-CD | Disulfiram | Brain cancer | [117] |
| Cationic CD coated magnetic nanoparticles | Methotrexate | Bone cancer | [120] |
| Magnetic hyperbranched β-CD | Doxorubicin | Bone cancer | [121] |
| Polyethylenimine–bisphosphonate–CD ternary conjugates | Doxorubicin | Bone cancer | [122] |
| Hydroxypropyl-β-CD | Saikosaponin-d | Skin cancer | [128] |
| β-CD, γ-CD, and γ-CD functionalized with arginine-glycine-aspartic or arginine moieties | Doxorubicin and oxaliplatin | Lung cancer, liver cancer | [16] |
| β-CD | Acetylshikonin | Colorectal cancer, breast adenocarcinoma | [127] |